FDA Grants Nexus Pharmaceuticals Approval for Isoproterenol Hydrochloride Injection USP Generic for Isuprel
7 August 2017 - - Vernon Hills, Illinois-based generic sterile injectable products developer Nexus Pharmaceuticals has received approval from the US Food and Drug Administration for its Abbreviated New Drug Application for Isoproterenol Hydrochloride Injection, the company said.
Nexus Pharmaceuticals' Isoproterenol Hydrochloride Injection is available as a single dose vial containing 0.2 mg per 1mL or 1 mg/5 mL and is an AP Rated generic equivalent of Isuprel.
Isoproterenol Hydrochloride Injection USP is indicated for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy, for serious episodes of heart block, and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation) and for use in cardiac arrest until electric shock or pacemaker therapy is available.
Its also indicated for bronchospasm occurring during anesthesia, and as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.
Nexus Pharmaceuticals specializes in developing and marketing generic sterile injectable products.